JD Supra6h
Adapting to the IRA: Early Lessons Learned on the IRA’s Impact on Deal-Making, Drug Economics, and Business Strategy
More than two years after the passage of the Inflation Reduction Act (“IRA”) and the Centers for Medicare and Medicaid Services’ (“CMS’”) ...
Pharma companies welcome new year with 583 drug price hikes so far
Drugmakers have started 2025, implementing price hikes for 583 products within the first two days of the new year alone, ...
Ozempic, Trulicity among Medicare's priciest drugs, report finds
Novo Nordisk expects Ozempic, which has been on the market since 2017, will be on Medicare's list of drugs to negotiate ...
AARP1d
25 Top Medicare Part D Drugs Have Nearly Doubled in Price
People with Medicare Part D plans shoulder a share of the cost of their prescription drugs. Under the standard Part D benefit ...
emjreviews.com2d
Role of Empagliflozin in Weight Reduction for Diabetic Patients
Researchers concluded that empagliflozin offers a promising dual benefit for glucose control and weight reduction, with ...
STAT2d
With a major patent cliff coming, will JPM play host to some serious deal-making?
The drug industry is facing one of the largest patent cliffs in recent history. Will that mean dealmaking at the annual J.P.
Daily4d
Research Highlights Expanded Clinical Uses of SGLT2 Inhibitors
Long-term use of SGLT2 inhibitors has been linked to various positive cardiovascular outcomes, including decreased rates of ...